Výsledky vyhledávání - "ESMO annual congress 2019"

A phase II study of Monalizumab in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN): results of the I1 cohort of the EORTC-HNCG-1559 trial (UPSTREAM)

Autor: R Galot, C Le Tourneau, E Saada-Bouzid, A Daste, C Even, P Debruyne, S Henry, S Zanetta, A Rutten, L Licitra, JL Canon, MC Kamin, ESMO annual congress 2019

Publikováno v: Annals of Oncology, Vol. 30 (suppl 5) (2019), p. l 5) (2019)

Background Patients (pts) with RM SCCHN progressing after platinum have a median overall survival (OS) of 7-8 months with nivolumab or pembrolizumab. No other drug has shown meaningful activity in this setting. HLA-E is a non-classical MHC molecule t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1493::6961ded2849deb946c22b2af9b674494
https://hdl.handle.net/2078.1/226092

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání